Back to News
Market Impact: 0.35
Verastem Reports VS-7375 Data, Prices $250M Offering And Names New CEO; Shares Up In Premarket
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Verastem Oncology reported positive responses for investigational KRAS G12D inhibitor VS-7375 in a Phase 1/2 trial spanning pancreatic, lung and colorectal cancers. The article reports a 41% response rate in second-line-or-later pancreatic cancer and begins reporting a 43% rate, but the supplied text cuts off before identifying the corresponding cohort.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
VSTM0.75
More News
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Netwealth stock sliding today?
- Bending Spoons skyrockets 35% as Berkshire Hathaway makes $330 million investment
- Bending Spoons Stock Soars on Berkshire’s Increased Stake
- Ambani’s Jio seeks to raise $3.2B in what could be India’s biggest IPO
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate Consensus Estimates Platforms With AI
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More